
BioAge Labs, Inc.: stock overview
Price
$5.10
November 17, 2026Market cap $226M
What Ploutos Investor adds for BioAge Labs
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
BioAge Labs had revenue of $8.6M over the last 12 months and a net loss of $108M. It holds more cash than debt, by $284M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.
Its SEC filings- Market cap
- $226M
- 44.38M shares
- P/E
- –
- Revenue, 12 months
- $8.6M
- Net margin
- -1,253.6%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
2 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap
- $226M
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B
- 0.7
- FCF yield
- –
- Earnings yield
- –
Profitability
- Operating margin
- -1,401.8%
- Net margin
- -1,253.6%
- ROIC
- -28.7%
- ROIC, 5-year average
- -22.7%
- ROE
- -32.7%
Growth
Sorry, we do not have enough data
for the “Growth” group
Balance sheet
- Cash
- $284M
- Total debt
- $2.7M
- Of which operating leases
- $2.7M
- Net cash
- $284M
- Net debt / EBITDA
- –
- Interest cover
- -913.2x
- Current ratio
- 15.51
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +23.8%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- BioAge Labs, Inc.
- CIK
- 1709941
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 44.38M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with BIOA
- JNJJohnson & Johnson+0,00%Compare with BIOA
- ABBVAbbVie+0,00%Compare with BIOA
- UNHUnitedHealth+0,00%Compare with BIOA
- MRKMerck & Company+0,00%Compare with BIOA
- AMGNAmgen+0,00%Compare with BIOA
- TMOThermo Fisher Scientific+0,00%Compare with BIOA
- ABTAbbott Laboratories+0,00%Compare with BIOA
The full analysis
What do BioAge Labs's filings show?
These are BioAge Labs's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is BIOA's market cap?
BioAge Labs, Inc.'s market cap is $226M, at a price of $5.10 on November 17, 2026 and 44.38M shares.
How much revenue does BIOA have?
BioAge Labs had revenue of $8.6M over the last 12 months.
Does BIOA pay a dividend?
No. BioAge Labs paid no regular dividend over the last 12 months.
Where do the figures come from?
From BioAge Labs, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.